Kin Y Mok

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8687041/publications.pdf

Version: 2024-02-01

79 papers	12,086 citations	81900 39 h-index	71685 76 g-index

87 all docs	87 docs citations	87 times ranked	17451 citing authors

#	Article	IF	Citations
1	Largeâ€scale plasma proteomic profiling identifies a highâ€performance biomarker panel for Alzheimer's disease screening and staging. Alzheimer's and Dementia, 2022, 18, 88-102.	0.8	65
2	Demographics and Medication Use of Patients with Late-Onset Alzheimerâ€™s Disease in Hong Kong. Journal of Alzheimer's Disease, 2022, 87, 1205-1213.	2.6	3
3	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	7.9	63
4	Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. Lancet Neurology, The, 2021, 20, 107-116.	10.2	62
5	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
6	Identification of sixteen novel candidate genes for late onset Parkinsonâ€™s disease. Molecular Neurodegeneration, 2021, 16, 35.	10.8	41
7	The East Asian Parkinson Disease Genomics Consortium. Lancet Neurology, The, 2021, 20, 982.	10.2	3
8	A highâ€performance biomarker panel for Alzheimerâ€™s disease screening and staging identified by largeâ€scale plasma proteomic profiling. Alzheimer's and Dementia, 2021, 17, .	0.8	4
9	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44
10	Deep learning for polygenic score analysis for Alzheimer's disease risk prediction in the Chinese population.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e056625.	0.8	0
11	Blood transcriptome analysis for Alzheimer' disease in Hong Kong Chinese population.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e056643.	0.8	1
12	A multi-level developmental approach to exploring individual differences in Down syndrome: genes, brain, behaviour, and environment. Research in Developmental Disabilities, 2020, 104, 103638.	2.2	13
13	Genetic and polygenic risk score analysis for Alzheimer's disease in the Chinese population. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12074.	2.4	14
14	Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders. Brain, 2020, 143, 2771-2787.	7.6	50
15	Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R. Neurobiology of Disease, 2020, 146, 105079.	4.4	4
16	Evaluation of genetic risk for Alzheimerâ€™s disease in the Hong Kong Chinese population. Alzheimer's and Dementia, 2020, 16, e045142.	0.8	0
17	Differential Associations of Apolipoprotein E Îµ4 Genotype With Attentional Abilities Across the Life Span of Individuals With Down Syndrome. JAMA Network Open, 2020, 3, e2018221.	5.9	7
18	Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information. Nature Communications, 2020, 11, 1041.	12.8	22

#	Article	IF	Citations
19	Health comorbidities and cognitive abilities across the lifespan in Down syndrome. Journal of Neurodevelopmental Disorders, 2020, 12, 4.	3.1	85
20	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	7.7	15
21	Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and Europeans. JAMA Neurology, 2020, 77, 746.	9.0	170
22	C9orf72 intermediate repeats are associated with corticobasal degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathologica, 2019, 138, 795-811.	7.7	50
23	Non-coding variability at the APOE locus contributes to the Alzheimerâ€™s risk. Nature Communications, 2019, 10, 3310.	12.8	91
24	Reply to â€œDown Syndrome Cognitive Marker's Significance in Alzheimer's Disease and Dementia Managementâ€. Alzheimer's and Dementia, 2019, 15, 1238-1239.	0.8	0
25	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
26	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Populationâ€Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Movement Disorders, 2019, 34, 1851-1863.	3.9	47
27	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
28	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	3.9	21
29	Mitochondria function associated genes contribute to Parkinsonâ€™s Disease risk and later age at onset. Npj Parkinson's Disease, 2019, 5, 8.	5.3	95
30	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinsonâ€™s disease heritability. Npj Parkinson's Disease, 2019, 5, 6.	5.3	83
31	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2019, 11, 26.	6.2	56
32	Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurology, 2019, 76, 152.	9.0	110
33	Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimer's and Dementia, 2019, 15, 245-257.	0.8	68
34	Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimerâ€™s disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1697-1706.	7.1	71
35	Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. Neurobiology of Aging, 2018, 64, 159.e5-159.e8.	3.1	30
36	Response to the commentary of Yates RL and DeLuca GC on the study: HLA-DRB1*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 19, 168-170.	2.0	2

#	Article	IF	Citations
37	LRP10 in Î±-synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
38	Aging related cognitive changes associated with Alzheimer's disease in Down syndrome. Annals of Clinical and Translational Neurology, 2018, 5, 741-751.	3.7	64
39	Frequency of Loss of Function Variants in LRRK2 in Parkinson Disease. JAMA Neurology, 2018, 75, 1416.	9.0	66
40	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
41	Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype. Annals of Neurology, 2018, 84, 485-496.	5.3	37
42	Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome. Alzheimer's Research and Therapy, 2018, 10, 39.	6.2	43
43	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. Neurology, 2018, 90, e2059-e2067.	1.1	35
44	NeuroChip, an updated version of the NeuroX genotyping platform to rapidly screen for variants associated with neurological diseases. Neurobiology of Aging, 2017, 57, 247.e9-247.e13.	3.1	108
45	Lack of evidence for a role of genetic variation in TMEM230 in the risk for Parkinson's disease in the Caucasian population. Neurobiology of Aging, 2017, 50, 167.e11-167.e13.	3.1	24
46	A Man with Difficulty Chewing Gum and an Ominous Family History. , 2017, , 103-106.		0
47	The importance of understanding individual differences in Down syndrome. F1000Research, 2016, 5, 389.	1.6	151
48	HLA-DRB*1501 associations with magnetic resonance imaging measures of grey matter pathology in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 7, 47-52.	2.0	14
49	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
50	Astrogliopathy predominates the earliest stage of corticobasal degeneration pathology. Brain, 2016, 139, 3237-3252.	7.6	107
51	Additional rare variant analysis in Parkinsonâ€™s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. Human Molecular Genetics, 2016, 25, ddw348.	2.9	48
52	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
53	Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 633-641.	1.9	11
54	Screening a UK amyotrophic lateral sclerosis cohort provides evidence of multiple origins of the C9orf72 expansion. Neurobiology of Aging, 2015, 36, 546.e1-546.e7.	3.1	48

#	Article	IF	Citations
55	Genomewide association study in cervical dystonia demonstrates possible association with sodium leak channel. Movement Disorders, 2014, 29, 245-251.	3.9	43
56	A familial frontotemporal dementia associated with C9orf72 repeat expansion and dysplastic gangliocytoma. Neurobiology of Aging, 2014, 35, 444.e11-444.e14.	3.1	1
57	Parkinsonâ€™s disease in GTP cyclohydrolase 1 mutation carriers. Brain, 2014, 137, 2480-2492.	7.6	169
58	Polymorphisms in BACE2 may affect the age of onset Alzheimer's dementia in Down syndrome. Neurobiology of Aging, 2014, 35, 1513.e1-1513.e5.	3.1	41
59	Madras motor neuron disease (MMND) is distinct from the riboflavin transporter genetic defects that cause Brownâ€“Vialettoâ€“Van Laere syndrome. Journal of the Neurological Sciences, 2013, 334, 119-122.	0.6	12
60	Evidence that PICALM affects age at onset of Alzheimer's dementia in Down syndrome. Neurobiology of Aging, 2013, 34, 2441.e1-2441.e5.	3.1	35
61	Homozygosity analysis in amyotrophic lateral sclerosis. European Journal of Human Genetics, 2013, 21, 1429-1435.	2.8	12
62	A robust model for read count data in exome sequencing experiments and implications for copy number variant calling. Bioinformatics, 2012, 28, 2747-2754.	4.1	534
63	Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain, 2012, 135, 736-750.	7.6	392
64	Behavioral Variant Frontotemporal Lobar Degeneration with Amyotrophic Lateral Sclerosis with a Chromosome 9p21 Hexanucleotide Repeat. Frontiers in Neurology, 2012, 3, 136.	2.4	6
65	Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain, 2012, 135, 751-764.	7.6	293
66	O1â€05â€01: Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: Clinical, neuroanatomical and neuropathological features. Alzheimer's and Dementia, 2012, 8, P92.	0.8	0
67	The chromosome 9 ALS and FTD locus is probably derived from a single founder. Neurobiology of Aging, 2012, 33, 209.e3-209.e8.	3.1	115
68	Screening for C9ORF72 repeat expansion in FTLD. Neurobiology of Aging, 2012, 33, 1850.e1-1850.e11.	3.1	46
69	Familial Lund frontotemporal dementia caused by C9ORF72 hexanucleotide expansion. Neurobiology of Aging, 2012, 33, 1850.e13-1850.e16.	3.1	14
70	High frequency of the expanded C9ORF72 hexanucleotide repeat in familial and sporadic Greek ALS patients. Neurobiology of Aging, 2012, 33, 1851.e1-1851.e5.	3.1	44
71	LRBA gene deletion in a patient presenting with autoimmunity without hypogammaglobulinemia. Journal of Allergy and Clinical Immunology, 2012, 130, 1428-1432.	2.9	90
72	Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurology, The, 2012, 11, 323-330.	10.2	1,039

#	Article	IF	Citations
73	A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD. Neuron, 2011, 72, 257-268.	8.1	3,833
74	Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurology, The, 2010, 9, 986-994.	10.2	205
75	Identification of a novel THAP1 mutation at R29 aminoâ€acid residue in sporadic patients with earlyâ€onset dystonia. Movement Disorders, 2009, 24, 2428-2429.	3.9	32
76	Autonomic dysfunction in ALS: A preliminary study on the effects of intrathecal BDNF. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2005, 6, 100-103.	2.1	102
77	Cerebral Venous Thrombosis in Hong Kong. Cerebrovascular Diseases, 2001, 11, 282-283.	1.7	26
78	A multimodal neurophysiological assessment in terminal renal failure. Acta Neurologica Scandinavica, 1991, 83, 89-95.	2.1	6
79	Nocardia Peritonitis Complicating Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 1990, 10, 99-99.	2.3	11